A 35-year-old woman from Assam presents with a 4-month history of fever, weight loss, and abdominal swelling. She received 28 days of sodium stibogluconate 3 months ago for kala-azar, with initial clinical improvement. Now she has relapsed with fever, hepatosplenomegaly, and a hemoglobin of 7.8 g/dL. Bone marrow smear again shows amastigotes. Which of the following is the most appropriate management?

Explanation

## Diagnosis: SSG-Resistant Relapsed Visceral Leishmaniasis (Kala-azar) ### Clinical Recognition **Key Point:** This patient presents with relapse of visceral leishmaniasis within 6 months of completing sodium stibogluconate (SSG) therapy — a hallmark of **SSG-resistant disease**. The clinical picture (fever, hepatosplenomegaly, bone marrow amastigotes, anemia) confirms active visceral leishmaniasis, **not** post-kala-azar dermal leishmaniasis (PKDL), which presents with skin lesions after apparent cure. **High-Yield:** SSG resistance in India has risen dramatically, particularly in Bihar, Uttar Pradesh, and increasingly in Assam. Relapse within 6 months of SSG completion is a reliable marker of resistance and mandates a switch to a non-antimonial agent. ### Management of SSG-Resistant or Relapsed Kala-azar | Scenario | Preferred Agent | Dosing | Duration | Rationale | |----------|-----------------|--------|----------|-----------| | **SSG-resistant relapse (standard)** | **Liposomal amphotericin B** | 3 mg/kg/day IV | 10 days | WHO first-choice; superior safety profile | | SSG-resistant (resource-limited) | Amphotericin B deoxycholate | 1 mg/kg/day IV | 15 days | Effective but significant nephrotoxicity | | SSG-resistant (oral) | Miltefosine | 2.5 mg/kg/day PO | 28 days | Alternative; slower onset | | PKDL (skin lesions only) | Miltefosine or SSG | Variable | 12–24 weeks | Different entity; longer duration | ### Why Liposomal Amphotericin B (Option D) is Correct 1. **WHO and NVBDCP guidelines:** Liposomal amphotericin B (L-AmB) is the **recommended first-line treatment for SSG-resistant or relapsed visceral leishmaniasis** in India. It is preferred over conventional amphotericin B deoxycholate due to its superior safety profile and equivalent efficacy (>95% cure rate). *(WHO Technical Report Series 2010; NVBDCP National Drug Policy for Kala-azar 2019)* 2. **Safety advantage:** L-AmB causes significantly less nephrotoxicity (<10% vs. 30–80% with deoxycholate), less infusion-related reactions, and fewer electrolyte disturbances — making it the preferred agent regardless of baseline renal function. 3. **Efficacy:** Both formulations achieve >95% cure in resistant cases, but L-AmB is the preferred formulation per current international and national guidelines. 4. **Dosing:** 3 mg/kg/day IV for 10 days (total dose 30 mg/kg) is the established regimen for relapsed/resistant kala-azar. **Clinical Pearl (Harrison's Principles of Internal Medicine, 21st ed.):** Liposomal amphotericin B is the drug of choice for visceral leishmaniasis in immunocompetent patients with treatment failure or SSG resistance. Conventional amphotericin B deoxycholate is an acceptable alternative only when liposomal formulation is unavailable due to cost constraints. ### Why Other Options Are Incorrect - **Option A (Miltefosine):** Oral miltefosine is a valid alternative but is slower-acting and less preferred for a patient with significant anemia (Hb 7.8 g/dL) and active relapse requiring prompt parenteral therapy. - **Option B (Amphotericin B deoxycholate):** While effective, it carries a 30–80% risk of nephrotoxicity and is now considered second-choice to liposomal formulation per WHO/NVBDCP guidelines. It is used only when L-AmB is unavailable. - **Option C (Repeat SSG):** Contraindicated in SSG-resistant relapse. Repeating the same agent that failed is inappropriate and risks further resistance selection. **Mnemonic — L-AmB advantages: "LESS TOXIC"** — **L**iposomal, **E**ffective (>95%), **S**afer kidneys, **S**horter course (10 days), **T**argeted delivery, **O**ptimal for resistance, **X**-nephrotoxicity reduced, **I**nternational guideline preferred, **C**ure rate equivalent.